1702259-66-2 Usage
General Description
H3B-6527 is a potent and selective inhibitor of the splicing factor SF3b complex, which plays a crucial role in pre-mRNA splicing. By targeting SF3b, H3B-6527 can disrupt the splicing process and lead to the production of aberrant mRNA transcripts, ultimately inhibiting the growth of cancer cells. H3B-6527 has shown promising anti-cancer activity in preclinical studies, particularly in hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndromes. H3B-6527 is being investigated as a potential therapeutic agent for the treatment of various forms of cancer and may offer a new approach for targeting splicing abnormalities in cancer cells.
Check Digit Verification of cas no
The CAS Registry Mumber 1702259-66-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,0,2,2,5 and 9 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1702259-66:
(9*1)+(8*7)+(7*0)+(6*2)+(5*2)+(4*5)+(3*9)+(2*6)+(1*6)=152
152 % 10 = 2
So 1702259-66-2 is a valid CAS Registry Number.
1702259-66-2Relevant articles and documents
CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF
-
Page/Page column 33-34, (2016/11/02)
A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt